Key result
Molsidomine metabolite SIN-1A inhibits platelet activation in healthy volunteers and myocardial infarction patients.
Why the study?
Molsidomine and its active metabolite SIN-1A have antithrombotic properties that may be related to their antiplatelet activities, which require further characterization.
Answers are grounded in this paper and cite their sources.
In vitro antiplatelet effects of SIN-1A require in vivo confirmation; leaves open clinical antithrombotic translation.
Molsidomine or its active metabolite SIN-1A have antithrombotic properties in experimental models. This effect seems to be related, at least in part, to their antiplatelet activities. SIN-1A inhibited platelet adhesion to collagen, platelet aggregation, and the release reaction in in vitro experiments. SIN-1A acts as an early step of platelet activation by inhibiting calcium influx and phospholipase activity, which leads to inhibition of thromboxane formation and fibrinogen binding. Antiplatelet properties were observed after oral absorption in healthy volunteers and in patients with myocardial infarction after intravenous infusion.
No takes yet. Share an insight, caveat, or question.
Wautier et al. (1989) conducted a review in Myocardial infarction and healthy volunteers. SIN-1A (metabolite of Molsidomine) was evaluated. SIN-1A, an active metabolite of molsidomine, inhibited platelet activation in vitro and demonstrated antiplatelet properties in healthy volunteers and patients with myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: